Comparing the current results to its competitors, Keros Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by -98.76 %, despite the revenue increase by the most of its competitors of 5.72 %, recorded in the same quarter.
Keros Therapeutics Inc 's Comment on Competition and Industry Peers
The competitive landscape includes companies targeting the TGF-ß signaling pathways, such as Scholar Rock Holding Corporation, Biogen Inc., and Regeneron Pharmaceuticals, Inc. Competitors often possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. The industry experiences mergers and acquisitions that may consolidate resources among fewer competitors. Smaller or early-stage companies can also be significant competitors, particularly through collaborations with larger companies or research institutions. Competition extends to recruiting personnel, establishing clinical trial sites, enrolling patients, and acquiring complementary technologies. Commercial opportunities may be reduced if competitors develop products that are safer, more effective, more convenient, or less expensive. The timing of regulatory approvals and reimbursement availability also affect competitiveness.
January 25, 2025
Keros Therapeutics, Inc. (NASDAQ: KROS) has come under the investigative spotlight of Bragar Eagel and Squire, P.C. a law firm renowned for its representation of stockholder rights. On January 24, 2025, the firm announced that it is probing potential claims against Keros Therapeutics on behalf of its stockholders. This investigation raises significant questions regarding the company s adherence to federal securities laws and whether it has engaged in any practices that may be deemed unlawful. The timing of this inquiry is particularly poignant, as Keros Therapeutics has experienced a disconcerting decline in its stock performance over the past year. With a staggering 71.08% drop in share value, Keros has bee...
March 14, 2024
Keros Therapeutics, a clinical-stage biopharmaceutical company specializing in therapeutics targeting dysfunctional signaling of the transforming growth factor-beta (TGF-) family of proteins, has recently announced significant progress in the development of their novel drug, KER-050 (elritercept). The company has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for KER-050 in the treatment of anemia in adult patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS). This designation emphasizes the potential of KER-050 to address an unmet medical need and accelerate its approval process.Clinical Data Presentation at the 65th ASH Annual Meeting:In addit...
January 4, 2024
Keros Therapeutics, a clinical-stage biopharmaceutical company specializing in therapies targeting dysfunctional signaling of the transforming growth factor-beta (TGF-) protein family, has recently announced the pricing of an upsized public offering of its common stock. The offering consists of 3,500,000 shares of common stock, with an expected public offering price of $40.00 per share. This brings the total gross proceeds to Keros at an impressive $140.0 million, before accounting for underwriting discounts, commissions, and offering expenses. It is noteworthy that all the common stock being offered is from Keros itself.In addition to the initial offering, Keros has granted the underwriters a 30-day option ...
January 3, 2024
Keros Therapeutics to Charter a New Course in Obesity Treatment with KER-065LEXINGTON, Mass., Jan. 03, 2024 - In a significant announcement that is set to bring new hope for obesity treatments worldwide, Keros Therapeutics, Inc. (NASDAQ: KROS) has declared its intention to develop KER-065, an innovative ligand trap that ingeniously deters the action of TGF- ligands, including myostatin (GDF8) and activin A. As a clinical-stage biopharmaceutical company, Keros is dedicated to designing and marketing ground-breaking therapeutics to treat patients suffering from disorders tied to dysfunctional signaling of TGF- beta family of proteins.Having earned a reputation for its transformative therapeutics approach to tr...
Pepgen Inc is a biotechnology company that operates on a business model focused on developing and commercializing transformative therapies for genetic diseases. They leverage their expertise in synthetic biology and gene editing technologies to create novel peptide-based therapies that can address previously untreatable genetic conditions. Pepgen Inc aims to partner with healthcare organizations and pharmaceutical companies to bring their innovative treatments to market.
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Sources:
Keros Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Keros Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
